SURVEY How do you feel about Elon Musk's alliance with Donald Trump? Take our poll. OTC Markets OTCPK - Delayed Quote ? USD Eisai Co., Ltd. (ESAIY) Follow Compare 8.49 -0.15 (-1.74%) At close: 3:31 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada. PR Newswire ? 3 months ago ESAIY -1.74% ESALF -4.05% Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI? (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI?) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L PR Newswire ? 5 months ago ESAIY -1.74% ESALF -4.05% BIIB Eisai Completes Submission of LEQEMBI? (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI?) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with PR Newswire ? 6 months ago BIIB ESAIY -1.74% ESALF -4.05% Alzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue. Yahoo Finance ? 11 months ago GE BIIB LH Eisai reporting positive data on injectable Alzheimer’s drug Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently only administered via IV. Yahoo Finance’s Anjalee Khemlani breaks down what this means in terms of access and costs as concerns about side effects and formularies are evident. Pfizer (PFE) and BioNTech (BNTX) are also working together to develop a combo COVID-flu vaccine, showing positive data in its trial. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Yahoo Finance Video ? 11 months ago ESAIY -1.74% ESALF -4.05% BNTX EISAI PRESENTS NEW LEQEMBI? (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new data for LEQEMBI? (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 "Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials PR Newswire ? 11 months ago ESAIY -1.74% ESALF -4.05% BIIB Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is Nikkei 225 Return ESAIY Nikkei 225 YTD -31.60% +14.79% 1-Year -36.45% +22.88% 3-Year -45.31% +40.18%
